Back to Search
Start Over
Polypharmacy in Osteoporosis Treatment.
- Source :
-
Clinics in geriatric medicine [Clin Geriatr Med] 2022 Nov; Vol. 38 (4), pp. 715-726. Date of Electronic Publication: 2022 Sep 13. - Publication Year :
- 2022
-
Abstract
- In older adults, polypharmacy and osteoporosis frequently occur contemporaneously. Polypharmacy is increasingly recognized as a risk factor for hip and fall-related fractures. Treatments for osteoporosis include antiresorptive (alendronate, risedronate, zoledronic acid, ibandronate, denosumab) and osteoanabolic (teriparatide, abaloparatide, romosozumab) agents. Polypharmacy is associated with worse adherence to pharmacologic therapy. Thus, the selection of osteoporosis treatment should be individualized and based on a variety of factors, including underlying fracture risk (high vs very high risk), medical comorbidities, medication burden, as well as fracture risk reduction profiles, modes of administration, and side effects of treatment options.<br />Competing Interests: Disclosure The authors have nothing to disclose.<br /> (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Subjects :
- Aged
Alendronate therapeutic use
Denosumab therapeutic use
Diphosphonates adverse effects
Humans
Ibandronic Acid therapeutic use
Polypharmacy
Risedronic Acid therapeutic use
Teriparatide therapeutic use
Zoledronic Acid therapeutic use
Bone Density Conservation Agents adverse effects
Fractures, Bone
Osteoporosis drug therapy
Osteoporotic Fractures
Subjects
Details
- Language :
- English
- ISSN :
- 1879-8853
- Volume :
- 38
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Clinics in geriatric medicine
- Publication Type :
- Academic Journal
- Accession number :
- 36210087
- Full Text :
- https://doi.org/10.1016/j.cger.2022.05.011